MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition

Introduction: KRAS G12C mutations define a molecularly distinct subset of NSCLC for which targeted therapy with sotorasib has exhibited clinical efficacy. However, acquired resistance is inevitable. MET amplification has been described as a putative off-target resistance mechanism, although its clin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Richard Riedel, MD, Lea Ruge, MD, Malte Verheyen, MD, Felix John, MD, Heather Scharpenseel, MD, Lucia Nogova, MD, PhD, Sebastian Michels, MD, Rieke N. Fischer, MD, Anna Eisert, MD, Carolin Jakob, MD, Emanuel Niesen, MD, Jana Fassunke, MD, Janna Siemanowski-Hrach, MD, Carina Heydt, MD, Anne Bunck, MD, Udo Siebolts, MD, PhD, Sabine Merkelbach-Bruse, MD, PhD, Reinhard Buettner, MD, PhD, Jürgen Wolf, MD, PhD, Matthias Scheffler, MD, PhD
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-03-01
Col·lecció:	JTO Clinical and Research Reports
Matèries:	NSCLC KRAS G12C Sotorasib MET amplification Tyrosine kinase inhibitor resistance
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2666364325001432
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!